Tamoxifen 20 mg

Tamoxifen 20 mg contains tamoxifen citrate, a selective estrogen receptor modulator (SERM). In clinical medicine, it is FDA-approved for metastatic breast cancer, adjuvant therapy, and reduction of breast cancer incidence in high-risk women. In non-medical bodybuilding contexts, it is commonly referenced as a component of post-cycle therapy (PCT), though such use falls outside approved indications.

The clinical dose for breast cancer treatment is 20 to 40 mg daily, with doses exceeding 20 mg given in divided doses. For risk reduction, the dose is 20 mg daily for 5 years. In non-medical contexts, tamoxifen is commonly referenced at 20 mg daily for 4 to 6 weeks during PCT. These non-medical practices are not derived from controlled clinical trials.

Tamoxifen is itself used as a post-cycle therapy (PCT) compound rather than requiring PCT after use. It is not an anabolic steroid and does not suppress endogenous testosterone production. Instead, it acts as an estrogen receptor antagonist in the pituitary, stimulating LH and FSH release to help restore the pituitary-gonadal axis after suppression.

Tamoxifen competitively binds to estrogen receptors, blocking estrogen's effects in breast tissue. In the NSABP P-1 trial, tamoxifen reduced the incidence of invasive breast cancer by 44% in high-risk women. It has a terminal elimination half-life of approximately 5 to 7 days, supporting once-daily dosing.

After initiation of therapy, steady-state concentrations for tamoxifen are achieved in about 4 weeks, and steady-state concentrations for its major metabolite N-desmethyl tamoxifen are achieved in about 8 weeks. Clinical effects on breast cancer risk reduction are typically observed over years of treatment.

There is no universally established "best" SERM, and tamoxifen has not been validated in controlled trials specifically for post-steroid-cycle recovery. Clinical guidelines explicitly state that approved indications in male athletes do not exist and its use carries serious risks. Clomiphene is an alternative SERM commonly referenced in non-medical PCT contexts.

Tamoxifen and Clomiphene are both SERMs but have different receptor activity profiles and clinical applications. Tamoxifen is primarily used for breast cancer treatment and risk reduction, while clomiphene is used for ovulation induction. Tamoxifen acts as an estrogen agonist in the liver and bone, while clomiphene's activity profile differs.

Tamoxifen and Anastrozole have different mechanisms. Tamoxifen is a SERM that blocks estrogen receptors, while anastrozole is an aromatase inhibitor that reduces estrogen synthesis by blocking androgen-to-estrogen conversion. They are used for different purposes in non-medical contexts.

Tamoxifen 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. This is the standard clinical dose for adjuvant breast cancer therapy and risk reduction. In non-medical PCT contexts, 20 mg daily is commonly referenced as a standard dose.

Tamoxifen 20 mg is labeled at 20 mg of tamoxifen citrate per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.

No lab reports were provided for this specific product listing. For products with published laboratory reports, those results would apply to the specific tested sample and should not be interpreted as a measurement of every tablet or production batch.